KRAS and neoplasm: Recent studies indicate that measuring KRAS dosage can provide insights into tumor aggressiveness, guide treatment decisions, and improve personalized medicine, while emphasizing the need for standardized methods and integration with other biomarkers in clinical trials [15, 16, 17, 18, 19].